NCT01107054View on ClinicalTrials.gov

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2010

Conditions
Pulmonary DiseaseLung DiseaseMoxifloxacin
Interventions
DRUG

PF-00610355

An orally inhaled dose of PF-00610355 450 µg on days 1 to 4

DRUG

PF-00610355

An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4

DRUG

moxifloxacin

A single oral dose of moxifloxacin 400 mg on Day 4.

DRUG

placebo

A single oral dose of non-matched placebo on Day 4.

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY